Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions

被引:22
作者
Tuttle, Jamison B. [1 ]
Anderson, Marie [1 ]
Bechle, Bruce M. [1 ]
Campbell, Brian M. [1 ]
Chang, Cheng [1 ]
Dounay, Amy B. [1 ]
Evrard, Edelweiss [1 ]
Fonseca, Kari R. [1 ]
Gan, Xinmin [1 ]
Ghosh, Somraj [1 ]
Horner, Weldon [1 ]
James, Larry C. [1 ]
Kim, Ji-Young [1 ]
McAllister, Laura A. [1 ]
Pandit, Jayvardhan [1 ]
Parikh, Vinod D. [1 ]
Rago, Brian J. [1 ]
Salafia, Michelle A. [1 ]
Strick, Christine A. [1 ]
Zawadzke, Laura E. [1 ]
Verhoest, Patrick R. [1 ]
机构
[1] Pfizer Worldwide Res & Dev, Neurosci Med Chem, Groton, CT 06340 USA
关键词
kynurenine amino transferase; kynurenic acid; aryl hydrocarbon receptor; irreversible inhibition; hydroxamic acid; dose response modeling; in vivo microdialysis; schizophrenia; CATION-PI INTERACTIONS; KYNURENIC ACID; CEREBROSPINAL-FLUID; ELEVATED LEVELS; SCHIZOPHRENIA; RECEPTOR; SITE;
D O I
10.1021/ml300237v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k(inact)/K-i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
引用
收藏
页码:37 / 40
页数:4
相关论文
共 20 条
[1]  
Claffey M. M., Bicyclic and Tricyclic Compounds as KAT II inhibitors, Patent No. [WO2010146488, 2010146488]
[2]  
Copeland RA, 2005, EVALUATION ENZYME IN, V46, P1
[3]   Cation-π interactions in protein-protein interfaces [J].
Crowley, PB ;
Golovin, A .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 59 (02) :231-239
[4]   Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia [J].
Dounay, Arny B. ;
Anderson, Marie ;
Bechle, Bruce M. ;
Campbell, Brian M. ;
Claffey, Michelle M. ;
Evdokimov, Artem ;
Evrard, Edelweiss ;
Fonseca, Kari R. ;
Gan, Xinmin ;
Ghosh, Somraj ;
Hayward, Matthew M. ;
Horner, Weldon ;
Kim, Ji-Young ;
McAllister, Laura A. ;
Pandit, Jayvardhan ;
Paradis, Vanessa ;
Parikh, Vinod D. ;
Reese, Matthew R. ;
Rong, SuoBao ;
Salafia, Michelle A. ;
Schuyten, Katherine ;
Strick, Christine A. ;
Tuttle, Jamison B. ;
Valentine, James ;
Wang, Hong ;
Zawadzke, Laura E. ;
Verhoest, Patrick R. .
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (03) :187-192
[5]   Pyridoxal phosphate enzymes: Mechanistic, structural, and evolutionary considerations [J].
Eliot, AC ;
Kirsch, JF .
ANNUAL REVIEW OF BIOCHEMISTRY, 2004, 73 :383-415
[6]   Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia [J].
Erhardt, S ;
Blennow, K ;
Nordin, C ;
Skogh, E ;
Lindström, LH ;
Engberg, G .
NEUROSCIENCE LETTERS, 2001, 313 (1-2) :96-98
[7]   Pharmacological Manipulation of Kynurenic Acid Potential in the Treatment of Psychiatric Disorders [J].
Erhardt, Sophie ;
Olsson, Sara K. ;
Engberg, Goran .
CNS DRUGS, 2009, 23 (02) :91-101
[8]   Cation-π interactions in structural biology [J].
Gallivan, JP ;
Dougherty, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) :9459-9464
[9]  
HAN Q, 2010, J CELL MOL LIFE SCI, V67, P353, DOI DOI 10.1007/S00018-009-0166-4
[10]   The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression:: Physiopathological implications [J].
Hilmas, C ;
Pereira, EFR ;
Alkondon, M ;
Rassoulpour, A ;
Schwarcz, R ;
Albuquerque, EX .
JOURNAL OF NEUROSCIENCE, 2001, 21 (19) :7463-7473